Literature DB >> 33610350

How to treat neurogenic bladder and sexual dysfunction after spinal cord lesion.

P Denys1, E Chartier-Kastler2, A Even3, C Joussain3.   

Abstract

Neurogenic bladder and sexual dysfunction after spinal cord lesions are highly prevalent. The treatment algorithm for neurogenic bladder is well described. Clean intermittent self-catheterisation associated with treatment of neurogenic detrusor overactivity is the gold standard. Goals of treatment are twofold: i) control risk factors to avoid upper urinary tract complications, and ii) improve quality of life by treating incontinence when feasible. Lower urinary tract dysfunction is still a major cause of complications and hospitalisation. Sexual dysfunction must be addressed and treated and is at the top of patient expectations one year after injury.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Erectile dysfunction; Neurogenic bladder; Spinal cord injury; Urinary tract infection

Mesh:

Year:  2021        PMID: 33610350     DOI: 10.1016/j.neurol.2020.07.013

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

1.  Establishing a core outcome set for neurogenic bladder trials: study protocol for a scoping review and Delphi surveys.

Authors:  Yan Zhang; Yamin Chen; Mingming Niu; Yuanyuan Li; Jiaoyan Zhang; Li Zhang; Fangfang Wu; Qingyun Chen; Huijin Yu; Jinhui Tian
Journal:  Trials       Date:  2022-06-13       Impact factor: 2.728

2.  Identifying causal relationships of cancer treatment and long-term health effects among 5-year survivors of childhood cancer in Southern Sweden.

Authors:  Anders Holst; Jan Ekman; Magnus Petersson-Ahrholt; Thomas Relander; Thomas Wiebe; Helena M Linge
Journal:  Commun Med (Lond)       Date:  2022-03-02

Review 3.  Relationship between hyperuricemia with deposition and sexual dysfunction in males and females.

Authors:  A Sansone; Y Reisman; E A Jannini
Journal:  J Endocrinol Invest       Date:  2022-01-08       Impact factor: 5.467

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.